Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer

NCT05737303 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.

NCT NCT05737303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Phase
Phase 3
Overall status
Recruiting
Start date
November 27, 2023
Completion date
December 31, 2027
Enrollment
538 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian carcinoma stage iii, epithelial ovarian carcinoma stage iv, fallopian tube carcinoma stage iii, fallopian tube carcinoma stage iv, primary peritoneal carcinoma stage iii, primary peritoneal carcinoma stage iv